Rheumatoid Arthritis Market to Surge by 2034 as Next-Generation Biologics and JAK Inhibitors Gain Traction | DelveInsight
PR Newswire —
The rheumatoid arthritis market is estimated to change during the forecast period of 2025–2034, owing to the launch of emerging therapies such as rabeximod (Cyxone), TAS5315 (Taiho Pharmaceutical), AZD1163 and AZD6912 (AstraZeneca), Ocadusertib (Eli Lilly and Company), R-2487 (Rise...